This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The patient sample was identified through a retrospective case-note review. The review included 53,963 case notes, from which 1,182 patients to be included in the patient sample were identified. Of these patients, 133 started treatment with latanoprost, 59 started treatment with bimatoprost, and 152 were initially treated with beta-blockers. Power calculations indicated that the sample had a statistical power of 80% to exclude a 14% difference.
Study design
This was a multi-centre, retrospective cohort study. The patients were followed up for at least 6 months. The retrospective nature of the study meant that there was no loss to follow-up.
Analysis of effectiveness
The analysis of the study data was conducted on an intention to treat basis. The primary health outcomes assessed were: the persistency of therapy (calculated using Kaplan Meier analysis), intraocular pressure, the number of treatment changes, the number of adverse events, the number of medicines prescribed at 6 months, whether the initial medicine was changed or additional medicine added, and the number and type of glaucoma-related hospital visits.
The three patient groups were shown to be comparable in terms of their age, gender, diagnosis, and whether it was the right or left eye receiving treatment. There appears to have been some difference in the racial composition of the three patients groups.
Effectiveness results
The risk ratio of discontinuing a beta-blocker compared with latanoprost was 1.08 (95% confidence interval, CI: 1.01 -1.16). If latanoprost was compared with bimatoprost, the risk ratio of discontinuing was 1.15 (95% CI: 1.03 -1.27).
At 6 months the mean number of medicines prescribed was 1.1 in all three patient groups (standard deviations, SDs, were 0.3 for latanoprost, 0.4 for bimatoprost and 0.4 for beta-blockers; the difference was not significant).
The patients in the latanoprost group had a mean of 0.27 (SD=0.6) changes to medicine in the first 6 months, while those in the bimatoprost group had a mean of 0.45 (SD=0.8) medicine changes. Those patients initially given betablockers had a mean of 0.47 (SD=0.8) changes to their medication in the first 6 months. The difference between the three groups was statistically significant, (p<0.0001).
The only adverse event that was statistically different between the three treatment groups was conjunctival hyperaemia. This was experienced by 4.8% of the latanoprost group, 11.0% of the bimatoprost group and 1.5% of the beta-blockers group, (p<0.0001).
At 6 months, intraocular pressure was 17.7 mmHg (SD=4.4) for patients treated with latanoprost, 18.2 mmHg (SD=3.7) for patients treated with bimatoprost and 18.7 mmHg (SD=3.8) for patients treated with beta-blockers, (p<0.0001).
Sixty-seven of the 357 patients initially treated with latanoprost had their treatment altered, compared with 49 of the 146 patients treated with bimatoprost and 113 of the 335 patients initially treated with beta-blockers. This difference was statistically significant, (p<0.0001).
CRD COMMENTARY -Selection of comparators
This study compared monotherapy with latanoprost, bimatoprost and beta-blockers for the treatment of open-angle glaucoma and ocular hypertension. No rationale for the choice of these therapies was provided. These may not be the only appropriate treatment options, and you should consider how they relate to your own setting before applying the results of this study.
Validity of estimate of measure of effectiveness
The clinical effectiveness data used in this study were taken from a retrospective cohort study. The authors reported that this provided a more representative picture of the true effect of the three treatments than would be the case with a randomised controlled trial. They argued that patients who would agree to participate in a randomised controlled trial would not be representative of the whole patient population diagnosed with open-angle glaucoma and ocular hypertension. As they did not provide any evidence to support this, it was unclear how appropriate this idea is. However, several aspects of the study design used in this paper could have introduced the potential for bias. For example, the study does not consider what confounding factors might have influenced the initial choice of treatment for the patients included in this study. In addition, the lack of blinding might have introduced bias. The authors indicated that the three patient groups were broadly comparable at baseline in terms of socio-demographic characteristics, diagnosis and whether it was their right or left eye that was receiving treatment. However, they did not report whether the groups had comparable intraocular pressures. As intraocular pressure (rather than reduction in intraocular pressure) was used as the primary outcome, this has the potential to have a substantial impact on the study results. The authors did not compare their patient sample with the patient population, so it was unclear whether it was representative of patients diagnosed with open-angle glaucoma and ocular hypertension. The clinical data were analysed on an intention to treat basis and adverse events were included, which enhances the validity of the analysis.
Validity of estimate of measure of benefit
No measure of health benefit was combined with the cost data so, in effect, a cost-consequences analysis was performed. Please see the comments in the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
The cost perspective adopted was that of the health care insurer. The costs of medication, office visits and procedures were included in the study. The paper reported that staff time was not considered in the study, but the extent to which this was included in the costs for office visits and procedures was unclear. The difference between the resource use, medication costs, and office visit and procedure costs for each of the three patient groups was statistically tested, thus reducing the uncertainty around the results. However, the statistical test used was not reported and the difference between the total costs was not tested. Some resource use data were reported in the paper. Although this will assist the generalisability of the study, a more comprehensive breakdown of resource use and unit costs would have enhanced the generalisability of the results. The price year was not reported, which will prevent any future reflation exercises.
Other issues
The authors compared their findings with those from similar studies, but did not consider how their results could be generalised to other settings. The authors appear to have presented all appropriate data, but the difference between data relating to the initial 6 months of treatment and all data identified in the study was not always clear. The authors reported some limitations of the study. In particular, a prospective study design was not utilised and visits and timings were not standardised.
